AnodyneWiki

Mebufotenin

5-MeO-DMT
Mebufotenin
Salts
[]
Mebufotenin hydrochloride
Mebufotenin hydrochloride
Mebufotenin succinate
Mebufotenin succinate
Molecular structure drawn from PubChem coordinates
Physical properties
[]
Molecular mass218.29 g/mol [1]
Solubility>32.7 [ug/mL] (The mean of the results at pH 7.4) [1]
Predicted LogP1.5 [1]
Structural Identifiers
[]
Molecular formulaC13H18N2O
IUPAC name2-(5-methoxy-1H-indol-3-yl)-N,N-dimethylethanamine
SMILESCN(C)CCC1=CNC2=C1C=C(C=C2)OC
InChIInChI=1S/C13H18N2O/c1-15(2)7-6-10-9-14-13-5-4-11(16-3)8-12(10)13/h4-5,8-9,14H,6-7H2,1-3H3
InChIKeyZSTKHSQDNIGFLM-UHFFFAOYSA-N
CAS number1019-45-0
UNIIX0MKX3GWU9
PubChem CID1832
Pharmacokinetics[]
Onset* Inhalation: seconds or 3–4 min (but up to 10–15 min) * Intranasal: 3–15 min * Intramuscular: 1–6 min * Intravenous: ≤1 minute * Oral (with harmaline): 15–18 min
Elimination half-life* Intranasal: 15–26 min * Sublingual: 28 min[3]
Duration of action* Inhalation: 5–30 min, but up–1–2 hours * Intranasal: 45–70 min * Intramuscular: ≤60 min * Intravenous: 10 min * Oral (with harmaline) ≥3–4 hours
MetabolismOxidative deamination (monoamine oxidase), O-demethylation (CYP2D6)
Routes of administrationInhalation, insufflation, sublingual, rectal, intramuscular, intravenous, oral (with an monoamine oxidase inhibitor like harmaline)

Mebufotenin (also known as 5-Methoxy-N,N-dimethyltryptamine, N,N-Dimethyl-5-methoxytryptamine, Methylbufotenine, MeODMT, Bufotenine, O-methyl-, 3-(2-Dimethylaminoethyl)-5-methoxyindole, 1H-Indole-3-ethanamine, 5-methoxy-N,N-dimethyl-, Ct 4334, 5-Methoxy-N,N-dimethyl-1H-indole-3-ethanamine or 5-Methoxy-N,N-dimethyl-1H-indole-3-ethylamine) is a psychedelic substance of the tryptamine class.

Chemistry

Salts []

Mebufotenin is typically found in the form of its hydrochloride and succinate salts.

 []

Mebufotenin is achiral.

Mebufotenin matches Lipinski's rule of five.

There are currently 11 reagent-interactions on

ReagentColor changeDescription
Marquisyellow
Meckered - brown
Mandelindeep greenish brown
Liebermannbrown > black
Froehdefaint yellow
Robadopeno pink color change
Simon'sno blue color change
EhrlichPink > Purple
Hofmannyellow > green
Morrispale green
Zimmermannyellow/light orange

Subjective effects []

nervewing / 5-MeO-DMT []
Pilz / Mebufotenin []
Routes:
  • Smoked
Forms:
  • Freebase
Source:
  • NL RC Vendor: 5-MeO-DMT
Notes:
  • vaped via a ceramic coil vape

Experience reports

Erowid

There are currently 30 experience reports involving mebufotenin on : []

Reddit

There are currently 16 trip reports involving mebufotenin on : []

 []

  • Australia: Mebufotenin is a Schedule 9.
  • Brazil: Mebufotenin is a F2.[4]
  • United Kingdom: Mebufotenin is a Class A under the "Misuse of Drugs Act 1971".
  • United States: Mebufotenin is a Schedule I under the "Controlled Substances Act".
  • Germany: Mebufotenin is a Anlage I under the "Betäubungsmittelgesetz (BtMG)".
  • Other: Mebufotenin is a Illegal in China, Sweden, Turkey.

See also []

External links []

References []

  1. National Center for Biotechnology Information. PubChem Compound Summary for CID 1832, Mebufotenin. Accessed November 20, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/1832
  2. U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Mebufotenin. UNII: X0MKX3GWU9. Global Substance Registration System. Accessed November 20, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/X0MKX3GWU9
  3. Bistue Millón MB, Noguera L, Bruno D, Vita L, Zanino M, Kassuha DE, Ortiz JE, Feresin GE, Díaz-Dellavalle P, Orosco L, Garcés MA, Diez P, Albarracín SG, Bruno MA. Safety and tolerability of multiple sublingual microdoses of 5-MeO-DMT in adults with moderate symptoms of depression and/or anxiety: a randomized, double-blind, placebo-controlled study. Neuropsychopharmacology. July 2025; 50(11):1715–1723. PMID 40659913.
  4. RDC Nº 804 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial. Diário Oficial da União. 2023-07-24. https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-804-de-24-de-julho-de-2023-498447451

Data sources []

SourceStatusUpdated (UTC)
dosingmissing (no dosing statistics)2026-11-20 08:45:57
drugsprook2026-11-20 08:45:53
erowidok2026-11-20 08:45:55
gsrsok2026-11-20 08:45:54
hmdbmissing (hmdb.ca refused automated access to HMDB0002004)2026-11-20 08:45:53
keggmissing (no KEGG DRUG entry)2026-11-20 08:45:58
pubchemok2026-11-20 08:45:52
redditok2026-11-20 08:45:53
sidermissing (not in SIDER)2026-11-20 08:45:53
structureok2026-11-20 08:45:53
wikipediaok2026-11-20 08:45:53